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MTP gene mutationsAbstract Abetalipoproteinemia (ABL), or Bassen–Kornzweig syndrome, is a rare autosomal
recessive disorder of lipoprotein metabolism, characterized by fat malabsorption, hypocholes-
terolemia, retinitis pigmentosa, progressive neuropathy and acanthocytosis.
We report the case of a Tunisian male child born from consanguineous marriage. He presented at
the age of 4 months with failure to thrive, greasy stool and vomiting. His clinical phenotype and
serum lipid profile suggested the diagnosis of ABL. The MTP gene analysis revealed a novel
homozygous mutation [c.2313-2314delinsAA (p.771Tyr>x)]. The parents were heterozygous for
the same mutation.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Abetalipoproteinemia (ABL), also known as Bassen–
Kornzweig syndrome (OMIM#200100), is a rare autosomal
recessive disorder characterized by extremely low levels of
apoB-containing lipoproteins, fat malabsorption, fat-soluble
vitamins deficiency and acanthocytosis in infancy [1,2].
Deficiency of fat-soluble vitamins could lead to a number of
variable manifestations, including spinocerebellar degenera-
tion, coagulopathy, and pigmented retinopathy [2]. Plasmatotal cholesterol and triglyceride levels are extremely low and
apoB-containing lipoproteins are nearly absent in plasma.
Mutations in the gene encoding the large subunit of
microsomal triglyceride transfer protein (MTP) gene
(OMIM*157147) are responsible for the phenotype [3].
MTP gene encodes a protein required for the assembly and
secretion of apoB-containing lipoproteins in the liver and
intestine [4,5]. In presence of MTP deficiency, apoB cannot
be properly lipidated and undergoes rapid intracellular degra-
dation; for this reason apoB-containing lipoproteins are
almost undetectable in plasma. It seems that there is no race
preference for abetalipoproteinemia or familial hypobetal-
ipoproteinemia [6]. However, a conserved haplotype and a
common MTP mutation p.G865X0 with a carrier frequency
of 1:131 in Ashkenazi Jewish population has been reported [7].
Table 2 Plasma lipid profile.
Results Normal range
Cholesterol 0.7 mmol/l 4.4–5.2
Triglyceride 0.01 mmol/l 0.5–1.7
High density lipoprotein 0.73 mmol/l 1.1–1.9
Apolipoprotein B <0.22 g/l 0.55–1.25
Table 3 Liposoluble vitamins profile.
Vitamins Results Normal range
Vitamin A 1 (retinol) 0.85 lmol/l 1.55–3.3
Vitamin E (tocopherol) 0.86 mg/l 7–15
Vitamin K 148 ng/l 150–900
252 H. Barakizou et al.We describe in this paper the clinical phenotype and the
molecular genetics in a Tunisian child having a novel mutation
of MTP gene.
2. Case report
A Tunisian male child, first in the order of birth of healthy first
degree consanguineous parents, was admitted to hospital at
the age of 4 months. He presented with failure to thrive, greasy
stool and vomiting. On examination, weight was 3650 g (<5th
percentile), height was 56 cm (<5th percentile), and head cir-
cumference was 38.5 cm (3rd–15th percentile). His birth
weight, height and head circumference were respectively,
3050 g, 49 cm and 32.5 cm. The rest of the examination was
unremarkable.
Patient laboratory data are summarized in Table 1.
Screening for celiac disease, cow’s milk protein allergy,
sweat test and thyroid function was normal. The upper gas-
trointestinal endoscopy was normal too (particularly no yellow
discoloration of the small intestinal mucosal surface). The
abdominal sonography showed homogeneous hyperechogenic
pattern of the liver. No diagnosis was made.
At the age of 20 months, he developed frequent, loose,
semi-solid and light colored stools. He was managed as exo-
crine pancreatic insufficiency and improved slightly under a
restricted fat diet and pancreatic extracts. At the age of
28 months, he became pale and dehydrated and was hospital-
ized. Physical examination was unremarkable expect failure to
thrive, signs of dehydration and pale skin. The cell blood count
showed normochromic normocytic non regenerative anemia
and the bone marrow examination was normal. Low fat diet
and pancreatic extracts were maintained.
During the following years, the patient continued to have
frequent episodes of diarrhea with steatorrhea, the stools
became large, soft and sometimes even watery and oily. His
neurological development was normal.
At the age of 13 years, the diarrhea became again profuse.
The physical examination showed no significant abnormal
findings and especially no neurological, muscular or oph-
thalmic impairment.
Plasma total cholesterol, HDL-cholesterol, triglyceride and
concentrations were measured by a standard method after an
overnight fast. Apo lipoproteins were measured by
immunonephelometry. Low levels of total cholesterol, triglyc-
erides, Apolipoprotein B were detected (Table 2).Table 1 Laboratory findings.
Test Results Normal range
White blood cell count 10,940/lL 6000–15,000/lL
Neutrophils 53% 40–80%
Lymphocyte 47% 20–60%
Hemoglobin 10.8 mg/dL 10.5–14 mg/dL
Platelets 376  103/lL 150–450  103/lL
Red blood cell count 4.2  106/lL 3.8–5.5  106/lL
Aspartate aminotransferase 50 IU/L 15–55 IU/L
Alanine aminotransferase 25 IU/L 5–45 IU/L
Prothrombin time 13 s 12–14 s
Gamma-glutamyl transferase 18 IU/L 4–60 IU/L
Albumin alkaline phosphatase 762 IU/L 145–420 IU/LLow levels of fat-soluble vitamins (A,E,K) were also noted
(Table 3). Peripheral blood smear showed many acanthocytes.
On the assumption that proband had ABL, we sequenced
the MTP gene. Genomic DNA was isolated from whole blood
EDTA samples using the salting-out method. The promoter,
all exons and flanking intronic sequences of the MTP gene
were amplified by polymerase chain reaction (PCR) and
PCR products were sequenced on an automated ABI-
PRISM 310 Genetic Analyzer (Applied Biosystems).
This analysis revealed that the proband was homozygous
for a novel mutation in the exon 16 of the MTP gene:
c.2313-2314delinsAA (p.771Tyr>x). The proband’s parents
were heterozygous for the same mutation. The lipid profile
of proband’s brother was measured and was normal.
The patient was treated by low dietary fat and by supple-
mentation of fat soluble vitamins.
3. Discussion
ABL is a rare autosomal recessive disease which occurs in less
than 1 in one million persons characterized by the absence of
plasma apoB-containing lipoproteins.
ABL is caused by MTP gene frameshift, non-sense and
splice site mutations which are responsible for truncated forms
of MTP devoid of function [2]. Non conservative missense
mutations of MTP are also associated with the disorder
[2,8]. The 894 amino-acid protein product of MTP (also called
97-KDa subunit) forms a heterodimer with the ubiquitous
endoplasmic reticulum enzyme protein disulfide isomerase.
MTP acts as a chaperone that facilitates the transfer of lipids
onto apoB. Mutations that lead to the absence of a functional
97-KDa subunit cause ABL [2].
In addition to abetalipoproteinemia, MTP gene mutations
and its variations could be associated with central obesity, ele-
vated liver enzymes, and alcoholic fatty liver disease [5].
It has recently been demonstrated that MTP is also a cen-
tral regulator of CD1 function [9]. Importantly, CD1 dysfunc-
tion in ABL is caused specifically by deficiency in MTP and
not by its downstream effects on the metabolism of apoB-con-
taining lipoprotein particles [9]. In Tunisia, three cases of
abetalipoproteinemia and homozygous familial hypobetal-
ipoproteinemia have been already reported. Two of them were
found to be homozygous, respectively for two novel mutations
in intron 5 (c.619-3T > G) and in exon 8 (c.923 G> A) of the
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nucleotide deletion (c.2172delT) in exon 15 of APOB gene
[10]. In our report, we describe a novel mutation of MTP gene
[(c.2313-2314delins AA (p.771Tyr>x)] causing an ABL partic-
ular phenotype in a young Tunisian boy, born to consan-
guineous parents.
Patients with homozygous ABL show multisystem manifes-
tations and the diagnosis is usually made in infancy because of
failure to thrive, fat malabsorption and progressive degenera-
tive neurologic disease. Malabsorption of fat and fat-soluble
vitamins is responsible for vitamin E deficiency that could lead
to neuromuscular abnormalities and loss of deep tendon
reflexes. Neurological involvement in ABL may be the most
serious clinical manifestation. The onset of neurologic disease
usually begins in the first or second decade of life and in the
past often progressed to catastrophic disability, although some
patients inexplicably escaped serious affliction until much later
in life [2]. Our patient had no neurological signs over 13 years
despite low level of vitamin E.
One of the most striking laboratory features seen in patients
with ABL is the absence of plasma apoB-containing lipopro-
teins. Plasma triglyceride levels are usually low (less than
10 mg/dL) and cholesterol level ranges from 25 to 40 mg/dL.
Our patient lipide plasma profile was concordant.
The ABL phenotype is similar to homozygous familial
hypobetalipoproteinemia (OMIM#107730) a disorder caused
most frequently by mutations in APOB gene. ABL heterozy-
gous parents usually have normal plasma lipoprotein profiles,
while heterozygous familial hypobetalipoproteinemia parents
showed low total cholesterol and LDL-cholesterol plasma
levels [11,12].
The diagnosis of ABL should be promptly made in children
with malabsorption, acanthocytosis and hypocholesterolemia,
since appropriate management can prevent later in life compli-
cations. The diagnosis in our patient was late because of the
absence of specific clinical and endoscopic features at the early
course of the disease. Its genetic study allowed the identifica-
tion of a novel mutation among the Tunisian population.
We think that the analysis of the functional impact of this
new mutation is necessary in order to better understand the
particular phenotype presented by our patient.
ABL patients are treated by a low-fat diet (fat <30% of
total calories and preferably closer to 20%), with reduced
long-chain fatty acid). Oral fat-soluble vitamins supplementa-
tion is essential for the prevention and even reversal of some
neurological, hematological and ophthalmological complica-
tions [13,14]. Hegele and all recommend 100–300 IU/kg/day
of vitamin E, 100–400 IU/kg/day of vitamin A, 800–1200 IU/-
day of vitamin D and 5–35 mg/week of vitamin K. Serum vita-
min levels should be checked every year. However, these levels
do not reach the normal ranges even after years of treatment
and symptom stability and do not correlate with oral vitamins
dosage [4,14]. Therefore vitamins supplementation should be
adjusted according not only serum markers but also to clinical
signs [14].
In addition, these authors suggest that patients consume
1–2 teaspoons of oils rich in poly-unsaturated fatty acids (olive
or soybean oil) to ensure adequate intake of essential fatty
acids [14].
Prenatal diagnosis is possible when the causal mutations in
both parents are known. Management should be undertakenin specialized centers. The prognosis is severe, with a signifi-
cantly reduced life expectancy [15].
4. Conclusion
ABL is a rare disease of lipoprotein metabolism that has
drawn attention to the importance of the MTP gene in the
assembly and secretion of apoB-containing lipoproteins.
Without treatment, ABL symptoms can be debilitating in
most of the patients and life expectancy is reduced. Current
evidence suggests that early treatment with high oral doses
of combined vitamin A and E, if introduced early enough,
can reduce the potential severity of neuropathy and retinopa-
thy. However, there is still a need for novel therapeutic
approaches to ABL, since vitamin therapy alone is not suffi-
cient to completely control or cure this disease.
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